Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5314683 | 0.81 | MEN1 (0.62) | MEN1KMT2ASMN1; SMN2LMNAMAPT | |
| SCHEMBL7822083 | 0.78 | HDAC3 (0.71) | KMT2ASMN1; SMN2LMNAMAPTMAPK1 | |
| SCHEMBL6766645 | 0.77 | AR (0.60) | MEN1KMT2ASMN1; SMN2LMNAMAPT | |
| SCHEMBL791289 | 0.77 | MEN1 (0.71) | MEN1KMT2ASMN1; SMN2LMNAMAPT | |
| SCHEMBL6767027 | 0.74 | TSHR (0.54) | MEN1KMT2ALMNAMAPTALDH1A1 | |
| SCHEMBL1066412 | 0.74 | HDAC3 (0.74) | MEN1KMT2ALMNAMAPTMAPK1 | |
| SCHEMBL4075010 | 0.74 | AR (0.76) | MEN1KMT2ASMN1; SMN2LMNAMAPT | |
| SCHEMBL5605570 | 0.73 | DRD4 (0.57) | MEN1KMT2ASMN1; SMN2LMNAMAPT | |
| SCHEMBL5315547 | 0.73 | ALDH1A1 (0.62) | MEN1KMT2ASMN1; SMN2LMNAMAPT | |
| SCHEMBL7428355 | 0.73 | ITGB1 (0.59) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166594-B2 | Antibacterial activity | AVENTIS PHARMA S.A. (FR) | 2007-01-23 | — | — | US | disclosed |
| US-20030149004-A1 | Streptogramin derivatives, their preparation and compositions containing them | AVENTIS PHARMA S.A. | 2003-08-07 | — | — | US | disclosed |
| US-6569854-B1 | Virginamycins | AVENTIS PHARMA S.A. (FR) | 2003-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149004-A1 | Streptogramin derivatives, their preparation and compositions containing them | MRPL21, ABHD5, APEH | MEN1 4052/4885KMT2A 3790/4885SMN1; SMN2 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.